Hospital
Phc-Elko INC
Phc-Elko INC was paid $6.51M by Medicaid between Jan 2018 and Dec 2024, across 176 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoPHC-ELKO INC
ELKO, NV 89801
ELKO, NV 89801
33aNPI1770674350assigned 09/27/2006
33bProvider typeRural Acute Care Hospital
28Total paid$6.51M
24GClaims471,161
24DCodes billed176
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,075 | $1.20M | |
| 2019 | 83,693 | $1.16M | |
| 2020 | 67,115 | $952K | |
| 2021 | 70,994 | $887K | |
| 2022 | 71,780 | $908K | |
| 2023 | 67,393 | $835K | |
| 2024incomplete | 44,111 | $568K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 19,448 | 12,861 | $1.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 22,616 | 16,489 | $1.28M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 18% | 4,540 | 2,895 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 7,286 | 4,516 | $764K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 4,069 | 2,761 | $251K |
| G0378 | Hospital observation service, per hour | 3.2% | 1,450 | 821 | $208K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 4,958 | 4,471 | $160K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 847 | 573 | $154K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.9% | 695 | 488 | $122K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 493 | 309 | $85K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.2% | 766 | 431 | $80K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,769 | 1,425 | $52K |
164 more codes
| 80053 | Comprehensive metabolic panel | <1% | 30,181 | $51K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,048 | $51K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,612 | $34K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 396 | $30K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,333 | $29K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,914 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,135 | $25K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,130 | $22K |
| 80055 | <1% | 396 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,787 | $17K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 28 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,063 | $14K |
| 59025 | Fetal non-stress test | <1% | 687 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,655 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,284 | $12K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 204 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,013 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 672 | $11K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 181 | $11K |
| 84702 | <1% | 2,519 | $9K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 159 | $9K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 164 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,767 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,538 | $7K |
| 72131 | <1% | 43 | $6K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,125 | $5K |
| 83880 | <1% | 3,275 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 4,475 | $4K |
| 80050 | General health panel | <1% | 167 | $3K |
| 96376 | <1% | 3,935 | $3K | |
| 87070 | <1% | 902 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 151 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,060 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 959 | $3K |
| 0001A | <1% | 114 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 16 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,643 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,630 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,597 | $2K |
| 80061 | Lipid panel | <1% | 2,040 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 180 | $2K |
| 87040 | <1% | 3,134 | $2K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 86 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,623 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,647 | $1K |
| 87186 | <1% | 4,371 | $1K | |
| 85610 | <1% | 3,405 | $1K | |
| 0002A | <1% | 97 | $1K | |
| 84439 | <1% | 1,064 | $887.77 | |
| 76830 | Ultrasound, transvaginal | <1% | 38 | $863.35 |
| 93971 | <1% | 24 | $789.03 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 160 | $772.75 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,750 | $760.44 |
| 84484 | <1% | 7,807 | $735.27 | |
| 73564 | <1% | 226 | $669.31 | |
| 85730 | <1% | 1,864 | $593.56 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 400 | $573.17 |
| 73610 | <1% | 331 | $529.52 | |
| 83690 | <1% | 8,087 | $454.09 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,220 | $441.14 |
| 82947 | <1% | 3,127 | $404.49 | |
| 84703 | <1% | 3,267 | $317.90 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,770 | $314.76 |
| 87420 | <1% | 301 | $313.83 | |
| 83605 | <1% | 3,166 | $312.99 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,820 | $308.57 |
| 80179 | <1% | 1,275 | $307.56 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 516 | $301.64 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,476 | $294.32 |
| 83655 | <1% | 28 | $288.44 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 695 | $280.57 |
| 80143 | <1% | 1,316 | $279.60 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 40 | $275.54 |
| 87428 | <1% | 854 | $264.53 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,136 | $263.84 |
| 73130 | <1% | 153 | $257.55 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,901 | $249.72 |
| 85027 | <1% | 1,319 | $244.32 | |
| 81025 | <1% | 3,914 | $231.91 | |
| 81003 | <1% | 10,327 | $220.06 | |
| 87430 | <1% | 2,491 | $219.71 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,825 | $205.68 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,506 | $193.34 |
| 82950 | <1% | 299 | $168.93 | |
| 87581 | <1% | 1,043 | $167.58 | |
| 87486 | <1% | 1,041 | $167.58 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,050 | $167.58 |
| 87081 | <1% | 2,686 | $149.49 | |
| 87077 | <1% | 4,371 | $144.09 | |
| 73030 | <1% | 80 | $143.45 | |
| 82565 | <1% | 1,168 | $141.72 | |
| 85379 | <1% | 2,108 | $132.89 | |
| 74018 | <1% | 80 | $131.99 | |
| 73630 | <1% | 207 | $131.81 | |
| 81001 | <1% | 8,827 | $126.37 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,879 | $125.23 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 730 | $118.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,656 | $118.37 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 218 | $117.20 |
| 83735 | <1% | 1,376 | $115.62 | |
| 82150 | <1% | 2,705 | $111.90 | |
| 87899 | <1% | 205 | $110.87 | |
| 84520 | <1% | 688 | $103.73 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 84 | $94.69 |
| 72100 | <1% | 66 | $93.23 | |
| 86140 | <1% | 1,978 | $76.68 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,470 | $74.37 |
| 90715 | <1% | 127 | $69.16 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,810 | $66.65 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,956 | $59.72 |
| 84145 | <1% | 504 | $54.81 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 148 | $44.44 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,218 | $40.44 |
| 82550 | <1% | 764 | $31.02 | |
| 86850 | <1% | 259 | $28.67 | |
| 82553 | <1% | 807 | $22.77 | |
| 86803 | <1% | 186 | $22.15 | |
| 84436 | <1% | 586 | $18.76 | |
| 86701 | <1% | 205 | $17.52 | |
| 82728 | <1% | 14 | $14.61 | |
| 86677 | <1% | 311 | $12.21 | |
| 86780 | <1% | 116 | $11.70 | |
| 85652 | <1% | 218 | $9.08 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 161 | $9.08 |
| 87205 | <1% | 185 | $8.73 | |
| 85007 | <1% | 934 | $8.50 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,564 | $7.85 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,052 | $6.97 |
| 86901 | <1% | 827 | $6.12 | |
| 86900 | <1% | 827 | $6.12 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 255 | $5.20 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,225 | $4.45 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,626 | $2.64 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 437 | $2.11 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,236 | $1.28 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 28 | $0.90 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 186 | $0.70 |
| J3230 | Injection, chlorpromazine hcl, up to 50 mg | 0% | 45 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 192 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 27 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,944 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 297 | $0.00 |
| 0012A | 0% | 135 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 118 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 49 | $0.00 |
| 87507 | 0% | 98 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 615 | $0.00 |
| 0011A | 0% | 174 | $0.00 | |
| 91301 | 0% | 91 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 26 | $0.00 |
| 96368 | 0% | 17 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 21 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 19 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 27 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 146 | $0.00 |
| 84550 | 0% | 34 | $0.00 | |
| 84100 | 0% | 76 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 154 | $0.00 |
| 84156 | 0% | 16 | $0.00 | |
| 85378 | 0% | 179 | $0.00 | |
| 82248 | 0% | 40 | $0.00 | |
| 91300 | 0% | 113 | $0.00 | |
| 96367 | 0% | 35 | $0.00 | |
| 82570 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.